Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | FNTA | P49354 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 11/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 8/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20377643 | 1.00 | MEN1 (0.40) | MEN1KMT2AALDH1A1FNTAPKM | |
| SCHEMBL28455197 | 0.80 | MEN1 (0.38) | MEN1KMT2AALDH1A1FNTAPKM | |
| SCHEMBL3973447 | 0.78 | MEN1 (0.45) | MEN1KMT2AALDH1A1FNTAPKM | |
| SCHEMBL230169 | 0.77 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1FNTAPKM | |
| SCHEMBL19296597 | 0.77 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1FNTAPKM | |
| SCHEMBL20610531 | 0.77 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1FNTAPKM | |
| SCHEMBL6803552 | 0.74 | HMGCR (0.32) | — | |
| SCHEMBL15298488 | 0.71 | FNTA (0.46) | MEN1KMT2AALDH1A1FNTAMAPT | |
| SCHEMBL28107053 | 0.69 | KMT2A (0.45) | MEN1KMT2AALDH1A1FNTAPKM | |
| SCHEMBL14570384 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 537 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600926-B2 | Treatment compositions with modified amino acid dimers for delivering a benefit agent | THE PROCTER & GAMBLE COMPANY (US) | 2026-04-14 | — | — | US | claimed |
| US-20260000592-A1 | TREATMENT COMPOSITIONS WITH ESTERAMINES OR SALTS THEREOF | PROCTER & GAMBLE (US) | 2026-01-01 | — | — | US | claimed |
| US-12509643-B2 | Pro-benefit-agent compounds with carbon/nitrogen bonds | THE PROCTER & GAMBLE COMPANY (US) | 2025-12-30 | — | — | US | claimed |
| EP-3784707-B1 | STABLE POLYUREA MICROCAPSULE COMPOSITIONS | INT FLAVORS & FRAGRANCES INC (US) | 2025-12-24 | — | — | EP | claimed |
| US-12404479-B2 | Laundry detergent composition containing graft copolymer and benefit agent | THE PROCTER & GAMBLE COMPANY (US) | 2025-09-02 | — | — | US | claimed |
| US-12398341-B2 | Apparatus and compositions for improving scent delivery | THE PROCTER & GAMBLE COMPANY (US) | 2025-08-26 | — | — | US | claimed |
| EP-4581114-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Novozymes A/S (DK) | 2025-07-09 | — | — | EP | claimed |
| EP-4555060-A1 | LAUNDRY DETERGENT COMPOSITION CONTAINING GRAFT COPOLYMER AND BENEFIT AGENT | The Procter & Gamble Company (US) | 2025-05-21 | — | — | EP | claimed |
| US-20250129312-A1 | CONSUMER PRODUCT COMPOSITIONS WITH PERFUME ENCAPSULATES | PROCTER & GAMBLE (US) | 2025-04-24 | — | — | US | claimed |
| WO-2025051371-A1 | A FRAGRANCE PASTILLE | SYMRISE AG (DE) | 2025-03-13 | — | — | WO | claimed |
| EP-1894603-B1 | Encapsulation of bulky fragrance molecules | TAKASAGO PERFUMERY CO LTD (JP) | 2014-11-19 | — | — | EP | claimed |
| WO-2014116469-A1 | TREATMENT COMPOSITIONS COMPRISING MICROCAPSULES, PRIMARY OR SECONDARY AMINES, AND FORMALDEHYDE SCAVENGERS | THE PROCTER & GAMBLE COMPANY (US) | 2014-07-31 | — | — | WO | claimed |
| US-20140201927-A1 | TREATMENT COMPOSITIONS COMPRISING MICROCAPSULES, PRIMARY OR SECONDARY AMINES, and FORMALDEHYDE SCAVENGERS | THE PROCTER & GAMBLE COMPANY (US) | 2014-07-24 | — | — | US | claimed |
| EP-2757146-A1 | Treatment compositions comprising microcapsules, primary or secondary amines, and formaldehyde scavengers | The Procter & Gamble Company (US) | 2014-07-23 | — | — | EP | claimed |
| EP-2430140-A2 | PERFUME SYSTEMS | The Procter & Gamble Company (US) | 2012-03-21 | — | — | EP | claimed |
| EP-2257284-A2 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | MARY KAY INC. (US) | 2010-12-08 | — | — | EP | claimed |
| WO-2010132531-A2 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2010-11-18 | — | — | WO | claimed |
| US-20100287710-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-11-18 | — | — | US | claimed |
| WO-2009099890-A2 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | MARY KAY INC. (US) | 2009-08-13 | — | — | WO | claimed |
| US-20090197939-A1 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | MARY KAY INC. (US) | 2009-08-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197939-A1 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | MMP8, LOX, TYR | MEN1 4868/4885KMT2A 3020/4885ALDH1A1 236/4885 |
| US-12509643-B2 | Pro-benefit-agent compounds with carbon/nitrogen bonds | HGFAC, PROKR1, FABP2 | MEN1 1760/4885KMT2A 3251/4885ALDH1A1 544/4885 |
| US-20260000592-A1 | TREATMENT COMPOSITIONS WITH ESTERAMINES OR SALTS THEREOF | ARGLU1, DAO, PNISR | MEN1 4088/4885KMT2A 3051/4885ALDH1A1 4253/4885 |
| US-12600926-B2 | Treatment compositions with modified amino acid dimers for delivering a benefit agent | F2, C9, S100A8 | MEN1 3507/4885KMT2A 3763/4885ALDH1A1 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.